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1060fraction (EF). After a median follow-up of 907 days
(range 0 to 1,912 days), we observed 24 cardiac deaths
(14 HF, 1 MI, 9 sudden death) and 46 hospitalizations
for HF, leading to a total of 54 composite endpoints.
Seven patients died during the ﬁrst week and were
considered as periprocedural events.
AAC markedly inﬂuenced the occurrence of the
outcome in univariable analysis (tertiles 3 and 2 vs. 1
hazard ratio [HR]: 2.61; 95% conﬁdence interval [CI]:
1.31 to 5.20; p ¼ 0.006; þ1 Log increment of ACC
HR: 1.70; 95% CI: 1.15 to 2.50; p ¼ 0.007). Potential
confounders considered were either univariate pre-
dictors of events or signiﬁcant correlates of AAC.
In a ﬁrst multivariable Cox regression model ad-
justed for arterial approach, peripheral artery disease,
and previous coronary artery bypass grafting (or pre-
valence of coronary artery disease), AAC remained
predictive of the outcome (tertiles 3 and 2 vs. 1 HR:
2.50; 95% CI: 1.23 to 5.09; p ¼ 0.001; þ1 Log
increment of ACC HR: 1.70; 95% CI: 1.10 to 2.61;
p ¼ 0.016). Similar ﬁndings were observed in 2 other
multivariable models, 1 adjusted for EuroSCORE and
diabetes and the other adjusted for post-procedural
grade 2 aortic regurgitation and calciﬁcation of the
aortic ring. A sensitivity analysis performed after ex-
clusion of periprocedural events led to similar results.
This study shows that the extent of AAC is a strong
independent predictor of cardiac outcome after
TAVR. This is not likely to be due to a higher occur-
rence of MI; indeed, outcome was mainly driven by
HF while only 1 fatal MI was observed, which arose in
the periprocedural period and was not accounted for
in the sensitivity analysis. Furthermore, adjustments
for “coronary history” did not change the results. We
believe that the worse cardiac prognosis associated
with a high AAC score mainly reﬂects the conse-
quences of aortic stiffening on LV function (Figure 1)
(4). This is probably critical in TAVR patients, because
they often have aged vessels. For the moment,
methods to “destiffen” the aorta are limited, and AAC
should be considered primarily as a new powerful
criterion to reﬁne risk stratiﬁcation in usually
severely ill patients in whom the best option is not
easy to determine.Brahim Harbaoui, MD
Pierre-Yves Courand, MD
Paul Charles, MD
Raphael Dauphin, MD
Loic Boussel, MD, PhD
Olivier Jegaden, MD, PhD
Olivier Dubreuil, MD
Guy de Gevigney, MD, PhD
*Pierre Lantelme, MD, PhD*Hôpital de la Croix-Rousse
Cardiology Department
103 Grande Rue de la Croix-Rousse
69004 Lyon
France
E-mail: pierre.lantelme@chu-lyon.fr
http://dx.doi.org/10.1016/j.jacc.2014.11.061
Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose. Drs. Harbaoui and Courand contributed
equally to this work.R EF E RENCE S
1. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compli-
ance impacts signiﬁcantly on left ventricular afterload and function in aortic
stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005;46:
291–8.
2. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after
transcatheter aortic valve implantation in high-risk patients with severe aortic
stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implan-
tation) Registry. J Am Coll Cardiol 2011;58:2130–8.
3. Mory B, Ardon R, Yezzi AJ, Thiran J. Non-Euclidean image-adaptive radial
basis functions for 3D interactive segmentation. Proceedings of 2009 IEEE
12th International Conference on Computer Vision. New York, NY: IEEE, 2009:
787–94.
4. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular
events: the Framingham Heart Study. Circulation 2010;121:505–11.Considerations for
Drug Development
for Heart FailureI read with great interest the thoughtful editorial
by Greene and Gheorghiade (1) proposing rigorous
testing in a small homogenous cohort of patients
hospitalized with heart failure in early phase trials in
order to elucidate the mechanisms of action and
beneﬁt for maximal pairing of the new therapy with
subsequent phase III trial population. Considering
that the last heart failure drug approved by the Food
and Drug Administration was the combination of
hydralazine and isosorbide dinitrate in 2005, this
concept could be equally applied to outpatient heart
failure population.
In assessing the merit of this innovative approach,
however, 2 issues need to be taken into consideration:
1. Even if the new therapy is of proven beneﬁt in
the highly selected cohort, it will need to be
tested in a wider less selected cohort and having
more insight into the mechanism of action may
not necessarily help in selecting a wider patient
population.
2. Differences between trials and community patients
have long been recognized (2) and adoption of the
J A C C V O L . 6 5 , N O . 1 0 , 2 0 1 5 Letters
M A R C H 1 7 , 2 0 1 5 : 1 0 5 7 – 6 3
1061proposed new approach will likely undermine the
generalizability of the new therapy to a greater
extent.
In our zeal to maximize the likelihood that the study is
successful, we should not lose sight of the possibility
that the more selective the study population, the nar-
rower the scope of the application of the newer
intervention.
It may be that it is still appropriate to continue to
search for newer therapies that have wider applica-
tion (3) with more emphasis on effective utilization
of various biomarkers to maximally identify best
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We fully agree that narrow inclusion and exclusion
criteria within clinical trials limit generalizability of
study results to a smaller segment of the overall
population. However, heart failure (HF) is a clinical
syndrome and not a speciﬁc disease, representing a
ﬁnal common pathway for various admixtures of
cardiac and noncardiac abnormalities. This hetero-
geneity applies to chronic HF with reduced ejection
fraction, but is especially true for HF with preserved
ejection fraction (1) and hospitalized HF (HHF) pop-
ulations where randomized trials have consistently
failed to improve long-term patient outcomes (2).
Testing new molecules in HHF without the
rigorous early phase testing we suggest does not
preclude a subsequent positive trial result. However,
on the basis of past HHF trial experiences and
increasing understanding of the diversity in pre-
cipitants, amplifying factors, and cardiac substrates
among HHF patients, this approach fails to maximizethe chances of achieving a successful study result.
The traditional strategy has also proven expensive,
both in terms of direct ﬁnancial costs and opportunity
costs of investing several years for completion of
trials with lower probability of showing clinical
beneﬁt (3). Moreover, using heterogeneous pop-
ulations to test suboptimally understood therapies
increases the risk for any of 3 potential problematic
scenarios: 1) overall primary endpoint is met but a
segment of the study population derives no beneﬁt or
harm; 2) overall primary endpoint is not met, effec-
tively “killing” further drug development, but a
bidirectional drug effect exists whereby speciﬁc sub-
groups derive offsetting beneﬁt (i.e., a potentially
useful therapy is abandoned) and harm (4); and 3)
overall primary endpoint is met, but size of the effect
is small and despite regulatory approval, the therapy
is not widely accepted by payers.
We recognize the potential for discordance be-
tween efﬁcacy and “real world” clinical effectiveness
of therapies within medicine. We also appreciate the
differences in patient characteristics between HHF
clinical trials and registries (5). However, the “1 size
ﬁts all” approach to HHF drug development has
thus far failed to be productive (2). Rather, we favor
identifying the “disease” within HHF and targeting
the speciﬁc abnormality or process. A pragmatic
approach going forward would involve proving clear
clinical beneﬁt with a therapy in select HHF patients.
Subsequently, the therapy could be serially trialed in
additional patient subgroups for which sound bio-
logic plausibility may exist. Such an approach could
theoretically widen the application of the novel
therapy while, at minimum, provide a treatment
capable of helping an HHF patient subset. With over 1
million primary hospitalizations for HF annually in
the United States alone, improving outcomes for even
a segment of this population could yield enormous
public health beneﬁts.Stephen J. Greene, MD
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